Survival of Mesenchymal Stem Cells in Different Methods of Nebulization.

We compared survival of bone marrow mesenchymal stem cells after compressor, ultrasound, and mesh nebulization of the cell suspension over 10 min. Viability of stromal cells was best preserved after compressor nebulization (72%). Cell survival after ultrasonic nebulization was significantly lower (20%). After mesh nebulization, no live cells were found. Thus, compressor nebulization is the most preferable method of the production of cell aerosol for their delivery to the lower respiratory tract.

[Multicomponent vaccine VP-4 in the therapy of allergic diseases]. / Polikomponentnaia vaktsina VP-4 v terapii allergicheskikh zabolevanii.

In the present study the results of the polycomponent vaccine B[symbol: see text]-4 use for the therapy of patients with bronchial asthma (BA) and latex allergy were generalized. The vaccine was introduced by the nasal-subcutaneous or nasal-oral administration simultaneously with the basic therapy. Te studies were conducted first on limited groups of patients, then in the course of the State Trial with the use of placebo control. Excellent and good effect lasting for 1 year and over was registered in 36 patients (66.7%) out of 54 BA patients receiving the vaccine by the intranasal-subcutaneous method. Immunotherapy produced no positive effect in 13 patients (24.1%). Out of 35 examined patients receiving the vaccine by the intranasal oral method, excellent and good effect was registered in 26 patients (74.2%). No effect was registered in 4 patients (11.4%). In the group of 28 patients receiving placebo simultaneously with the basic therapy positive dynamics in the course of the disease was observed only in 3 patients. Treatment with polycomponent vaccine B[symbol: see text]-4 led to a prolonged (to a year and more) decrease in the frequency and severity of exacerbations, contributed to the prolongation of remissions and to a decrease in the amount of administered medicinal preparations, especially systemic corticosteroids. Immunotherapy ensured the correction of the content of lymphocyte subpopulations with markers CD3, CD4, CD72 and a rise in the titers of antibodies to antigens contained in the preparation. The use of therapeutic polycomponent vaccine B[symbol: see text]-4 for the treatment of patients with latex allergy ensured the state of prolonged remission in this group of patients. On the basis of our investigations we believe that the use of the therapeutic polycomponent vaccine B[symbol: see text]-4 may be included into the basis therapy of allergic diseases.

[Approaches to prevention and treatment of latex allergy]. / Podkhody k profilaktike i lecheniiu lateksnoi allergii.

Data on sensitization to latex as well as measures aimed at prevention and treatment of latex allergy, are presented. The intensity of the symptoms manifestation of latex allergy was shown to depend on the duration of contact with latex. To prevent the development of latex allergy, the following preparations were used: the antihistaminic preparation Claritine, the immunocorrecting preparations Ruzam and polycomponent vaccine VP-4. The use of Claritine was shown to lead to the alleviation of the symptoms of latex allergy, but after treatment with Claritine was stopped the symptoms of latex allergy reappeared. The clinical effect lasted for as long as 2 months after treatment with Ruzam, while in case of polycomponent vaccine VP-4 use remission was registered even 3 months later. The data presented thus confirm topicality of the latex allergy problem and practical importance of using the immunocorrecting preparations Ruzam and polycomponent vaccine VP-4 for its prevention and treatment.

[The immunotherapy of bronchial asthma with a multicomponent vaccine administered intranasally and orally]. / Immunoterapiia bronkhial'noi astmy polikomponentnoi vaktsinoi pri intranazal'no-oral'nom vvedenii.

Multicomponent vaccine prepared from opportunistic bacteria, when administered intranasally and orally to patients with bronchial asthma and chronic bronchitis, was well tolerated by the patients. Side effects induced by the vaccine in a few patients lasted for a short time and were mainly local. Immunotherapy with the vaccine led to a decrease in the severity of the course of the disease, as well as in the frequency and severity of exacerbations. In 26 out of 35 adult patients (74.3%) good and excellent effect was noted; during the observation of 20 sick children aged up to 3 years for a period of 1 year similar effect was noted in 60% of cases. Vaccinal therapy, in addition to its main effect, also contributed to a considerable drop in the morbidity rate of acute respiratory diseases among susceptible children.

[The effect of immunotherapy with cell-free vaccines made from the antigens of opportunistic microorganisms on the dynamics of DNA antibody formation]. / Izuchenie vliianiia immunoterapii beskletochnymi vaktsinami iz antigenov uslovno-patogennykh mikroorganizmov na dinamiku obrazovaniia antitel k DNK.

The sera of patients subjected to immunotherapy with staphylococcal vaccine and with multicomponent vaccine (i.e. the mixture of the antigenic preparations of Staphylococcus aureus, Klebsiella pneumoniae, Proteus vulgaris, Escherichia coli) were studied by the method of the enzyme immunoassay on the basis of cattle spleen DNA. Immunotherapy with staphylococcal vaccine was given to patients with dermal diseases, chronic obstructive bronchitis and pulmonary abscess. Multicomponent vaccine was introduced to patients with the infectious allergic form of bronchial asthma, moderate or severe. Immunotherapy with both preparations under study was shown to produce no accumulation of antibodies to native and denatured DNA.